Lozano R, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–128.
Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA. 2003;290(2):199–206.
Ostchega Y, et al. Trends of elevated blood pressure among children and adolescents: data from the National Health and Nutrition Examination Survey 1988–2006. Am J Hypertens. 2009;22(1):59–67.
Barker DJ, et al. Growth in utero, blood pressure in childhood and adult life, and mortality from cardiovascular disease. BMJ. 1989;298(6673):564–7.
Moritz KM, et al. Developmental programming of a reduced nephron endowment: more than just a baby’s birth weight. Am J Physiol Renal Physiol. 2009;296(1):F1–9.
Lurbe E, et al. Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens. 2009;27(9):1719–42.
Chiolero A, et al. Prevalence of hypertension in schoolchildren based on repeated measurements and association with overweight. J Hypertens. 2007;25(11):2209–17.
Chiolero A, et al. Discordant secular trends in elevated blood pressure and obesity in children and adolescents in a rapidly developing country. Circulation. 2009;119(4):558–65.
Portman RJ, et al. Pediatric hypertension: diagnosis, evaluation, management, and treatment for the primary care physician. Curr Probl Pediatr Adolesc Health Care. 2005;35(7):262–94.
Brown NJ. Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat Rev Nephrol. 2013;9(8):459–69.
Bondanelli M, Ambrosio MR, degli Uberti EC. Pathogenesis and prevalence of hypertension in acromegaly. Pituitary. 2001;4(4):239–49.
Kamenicky P, et al. Body fluid expansion in acromegaly is related to enhanced epithelial sodium channel (ENaC) activity. J Clin Endocrinol Metab. 2011;96(7):2127–35.
Rosskopf D, et al. Genetics of arterial hypertension and hypotension. Naunyn Schmiedebergs Arch Pharmacol. 2007;374(5–6):429–69.
Stabouli S, Kotsis V, Zakopoulos N. Ambulatory blood pressure monitoring and target organ damage in pediatrics. J Hypertens. 2007;25(10):1979–86.
Guyton AC. Long-term arterial pressure control: an analysis from animal experiments and computer and graphic models. Am J Physiol. 1990;259(5 Pt 2):R865–77.
Ivy JR, Bailey MA. Pressure natriuresis and the renal control of arterial blood pressure. J Physiol. 2014;592(Pt 18):3955–67.
Rettig R, Grisk O. The kidney as a determinant of genetic hypertension: evidence from renal transplantation studies. Hypertension. 2005;46(3):463–8.
Crowley SD, et al. Distinct roles for the kidney and systemic tissues in blood pressure regulation by the renin-angiotensin system. J Clin Invest. 2005;115(4):1092–9.
Curtis JJ, et al. Remission of essential hypertension after renal transplantation. N Engl J Med. 1983;309(17):1009–15.
Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell. 2001;104(4):545–56.
Fava C, et al. 24-h ambulatory blood pressure is linked to chromosome 18q21-22 and genetic variation of NEDD4L associates with cross-sectional and longitudinal blood pressure in Swedes. Kidney Int. 2006;70(3):562–9.
Fava C, et al. Subjects heterozygous for genetic loss of function of the thiazide-sensitive cotransporter have reduced blood pressure. Hum Mol Genet. 2008;17(3):413–8.
Kobori H, et al. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev. 2007;59(3):251–87.
Lombardi D, et al. Salt-sensitive hypertension develops after short-term exposure to Angiotensin II. Hypertension. 1999;33(4):1013–9.
Franco M, et al. Impaired pressure natriuresis resulting in salt-sensitive hypertension is caused by tubulointerstitial immune cell infiltration in the kidney. Am J Physiol Renal Physiol. 2013;304(7):F982–90.
DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev. 1997;77(1):75–197.
DiBona GF, Esler M. Translational medicine: the antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol. 2010;298(2):R245–53.
Julius S. Autonomic nervous system dysregulation in human hypertension. Am J Cardiol. 1991;67(10):3B–7.
Krum H, et al. Novel procedure- and device-based strategies in the management of systemic hypertension. Eur Heart J. 2011;32(5):537–44.
Patrono C. The PGH-synthase system and isozyme-selective inhibition. J Cardiovasc Pharmacol. 2006;47 Suppl 1:S1–6.
Harris Jr RC. Cyclooxygenase-2 inhibition and renal physiology. Am J Cardiol. 2002;89(6A):10D–7.
Harris RC, et al. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest. 1994;94(6):2504–10.
Lin L, et al. Role of prostanoids in renin-dependent and renin-independent hypertension. Hypertension. 1991;17(4):517–25.
Fujino T, et al. Decreased susceptibility to renovascular hypertension in mice lacking the prostaglandin I2 receptor IP. J Clin Invest. 2004;114(6):805–12.
Cinotti GA, Pugliese F. Prostaglandins and hypertension. Am J Hypertens. 1989;2(2 Pt 2):10S–5.
Hornych A, et al. Thromboxane B2 in borderline and essential hypertensive patients. Prostaglandins Leukot Med. 1983;10(2):145–55.
Sowers JR, et al. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med. 2005;165(2):161–8.
Folkow B. Acute effects of pressure on resistance vessel geometry. Acta Physiol Scand. 1978;104(4):496–8.
Takeshita A, Mark AL. Decreased vasodilator capacity of forearm resistance vessels in borderline hypertension. Hypertension. 1980;2(5):610–6.
Mulvany MJ. Small artery remodelling in hypertension. Basic Clin Pharmacol Toxicol. 2012;110(1):49–55.
Bakker EN, et al. Organoid culture of cannulated rat resistance arteries: effect of serum factors on vasoactivity and remodeling. Am J Physiol Heart Circ Physiol. 2000;278(4):H1233–40.
Bakker EN, et al. Small artery remodeling depends on tissue-type transglutaminase. Circ Res. 2005;96(1):119–26.
Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med. 1990;323(1):27–36.
Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288(5789):373–6.
Konishi M, Su C. Role of endothelium in dilator responses of spontaneously hypertensive rat arteries. Hypertension. 1983;5(6):881–6.
Luscher TF, Raij L, Vanhoutte PM. Endothelium-dependent vascular responses in normotensive and hypertensive Dahl rats. Hypertension. 1987;9(2):157–63.
Panza JA, et al. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med. 1990;323(1):22–7.
Miller MJ, Pinto A, Mullane KM. Impaired endothelium-dependent relaxations in rabbits subjected to aortic coarctation hypertension. Hypertension. 1987;10(2):164–70.
Taddei S, et al. Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation. 1995;91(7):1981–7.
Huang PL, et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature. 1995;377(6546):239–42.
Van Vliet BN, Chafe LL, Montani JP. Characteristics of 24 h telemetered blood pressure in eNOS-knockout and C57Bl/6J control mice. J Physiol. 2003;549(Pt 1):313–25.
Schiffrin EL. A critical review of the role of endothelial factors in the pathogenesis of hypertension. J Cardiovasc Pharmacol. 2001;38 Suppl 2:S3–6.
Kurtz A, Wagner C. Role of nitric oxide in the control of renin secretion. Am J Physiol. 1998;275(6 Pt 2):F849–62.
Yanagisawa M, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332(6163):411–5.
Luscher TF, Seo BG, Buhler FR. Potential role of endothelin in hypertension. Controversy on endothelin in hypertension. Hypertension. 1993;21(6 Pt 1):752–7.
Rabelink TJ, et al. Effects of endothelin-1 on renal function in humans: implications for physiology and pathophysiology. Kidney Int. 1994;46(2):376–81.
Kohan DE. Endothelins in the normal and diseased kidney. Am J Kidney Dis. 1997;29(1):2–26.
Ahn D, et al. Collecting duct-specific knockout of endothelin-1 causes hypertension and sodium retention. J Clin Invest. 2004;114(4):504–11.
Ishikawa T, et al. Positive inotropic action of novel vasoconstrictor peptide endothelin on guinea pig atria. Am J Physiol. 1988;255(4 Pt 2):H970–3.
Schiffrin EL. Vascular endothelin in hypertension. Vascul Pharmacol. 2005;43(1):19–29.
Schiffrin EL. The angiotensin-endothelin relationship: does it play a role in cardiovascular and renal pathophysiology? J Hypertens. 2003;21(12):2245–7.
Gariepy CE, et al. Salt-sensitive hypertension in endothelin-B receptor-deficient rats. J Clin Invest. 2000;105(7):925–33.
Ergul S, et al. Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension. Hypertension. 1996;28(4):652–5.
Granger JP, et al. Pathophysiology of hypertension during preeclampsia linking placental ischemia with endothelial dysfunction. Hypertension. 2001;38(3 Pt 2):718–22.
Zhou J, et al. Gestational hypoxia induces preeclampsia-like symptoms via heightened endothelin-1 signaling in pregnant rats. Hypertension. 2013;62(3):599–607.
Krum H, et al. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N Engl J Med. 1998;338(12):784–90.
Nakov R, et al. Darusentan: an effective endothelinA receptor antagonist for treatment of hypertension. Am J Hypertens. 2002;15(7 Pt 1):583–9.
Flegal KM, et al. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA. 2012;307(5):491–7.
Bretzel RG. Can we further slow down the progression to end-stage renal disease in diabetic hypertensive patients? J Hypertens Suppl. 1997;15(2):S83–8.
Hall JE. The kidney, hypertension, and obesity. Hypertension. 2003;41(3 Pt 2):625–33.
Vogt B, Bochud M, Burnier M. The association of aldosterone with obesity-related hypertension and the metabolic syndrome. Semin Nephrol. 2007;27(5):529–37.
Goodfriend TL, et al. Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension. 2004;43(2):358–63.
da Silva AA, et al. The role of the sympathetic nervous system in obesity-related hypertension. Curr Hypertens Rep. 2009;11(3):206–11.
Schwartz MW, et al. Central nervous system control of food intake. Nature. 2000;404(6778):661–71.
da Silva AA, do Carmo JM, Hall JE. Role of leptin and central nervous system melanocortins in obesity hypertension. Curr Opin Nephrol Hypertens. 2013;22(2):135–40.
Prior LJ, et al. Exposure to a high-fat diet alters leptin sensitivity and elevates renal sympathetic nerve activity and arterial pressure in rabbits. Hypertension. 2010;55(4):862–8.
Mark AL. Selective leptin resistance revisited. Am J Physiol Regul Integr Comp Physiol. 2013;305(6):R566–81.
Wang ZV, Scherer PE. Adiponectin, cardiovascular function, and hypertension. Hypertension. 2008;51(1):8–14.
Ouchi N, et al. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension. 2003;42(3):231–4.
Tanida M, et al. Effects of adiponectin on the renal sympathetic nerve activity and blood pressure in rats. Exp Biol Med (Maywood). 2007;232(3):390–7.
Sarafidis PA, Bakris GL. Review: insulin and endothelin: an interplay contributing to hypertension development? J Clin Endocrinol Metab. 2007;92(2):379–85.
Manrique C, Lastra G, Sowers JR. New insights into insulin action and resistance in the vasculature. Ann N Y Acad Sci. 2014;1311:138–50.
de Bold AJ, et al. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 1981;28(1):89–94.
Iida T, et al. Brain natriuretic peptide is cosecreted with atrial natriuretic peptide from porcine cardiocytes. FEBS Lett. 1990;260(1):98–100.
Nakao K, et al. Molecular biology and biochemistry of the natriuretic peptide system. I: natriuretic peptides. J Hypertens. 1992;10(9):907–12.
Kario K, et al. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study. Hypertension. 2014;63(4):698–705.
Fluckiger JP, et al. Effect of atriopeptin III on hematocrit and volemia of nephrectomized rats. Am J Physiol. 1986;251(4 Pt 2):H880–3.
Volpe M, et al. Effect of atrial natriuretic factor on blood pressure, renin, and aldosterone in Goldblatt hypertension. Hypertension. 1985;7(3 Pt 2):I43–8.
de Wardener HE. The hypothalamus and hypertension. Physiol Rev. 2001;81(4):1599–658.
John SW, et al. Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science. 1995;267(5198):679–81.
Lopez MJ, et al. Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature. 1995;378(6552):65–8.
Steinhelper ME, Cochrane KL, Field LJ. Hypotension in transgenic mice expressing atrial natriuretic factor fusion genes. Hypertension. 1990;16(3):301–7.
Jin HK, et al. Impaired release of atrial natriuretic factor in NaCl-loaded spontaneously hypertensive rats. Hypertension. 1988;11(6 Pt 2):739–44.
Schiffrin EL, St-Louis J, Essiambre R. Platelet binding sites and plasma concentration of atrial natriuretic peptide in patients with essential hypertension. J Hypertens. 1988;6(7):565–72.
Talartschik J, et al. Low atrial natriuretic peptide plasma concentrations in 100 patients with essential hypertension. Am J Hypertens. 1990;3(1):45–7.
Ferrari P, et al. Dysregulation of atrial natriuretic factor in hypertension-prone man. J Clin Endocrinol Metab. 1990;71(4):944–51.
Campese VM, et al. Salt intake and plasma atrial natriuretic peptide and nitric oxide in hypertension. Hypertension. 1996;28(3):335–40.
Cannone V, et al. Atrial natriuretic peptide genetic variant rs5065 and risk for cardiovascular disease in the general community: a 9-year follow-up study. Hypertension. 2013;62(5):860–5.
Rubattu S, Sciarretta S, Volpe M. Atrial natriuretic peptide gene variants and circulating levels: implications in cardiovascular diseases. Clin Sci (Lond). 2014;127(1):1–13.
Margolius HS, et al. Urinary kallikrein excretion in hypertension. Circ Res. 1972;31 Suppl 2:125–31.
Levy SB, et al. Urinary kallikrein and plasma renin activity as determinants of renal blood flow. The influence of race and dietary sodium intake. J Clin Invest. 1977;60(1):129–38.
Alfie ME, et al. Effect of high salt intake in mutant mice lacking bradykinin-B2 receptors. Hypertension. 1997;29(1 Pt 2):483–7.
Majima M, et al. High sensitivity to salt in kininogen-deficient brown Norway Katholiek rats. Hypertension. 1993;22(5):705–14.
Madeddu P, et al. Chronic kinin receptor blockade induces hypertension in deoxycorticosterone-treated rats. Br J Pharmacol. 1993;108(3):651–7.
Wang J, et al. Human tissue kallikrein induces hypotension in transgenic mice. Hypertension. 1994;23(2):236–43.
Berry TD, et al. A gene for high urinary kallikrein may protect against hypertension in Utah kindreds. Hypertension. 1989;13(1):3–8.
Zinner SH, et al. Familial aggregation of urinary kallikrein concentration in childhood: relation to blood pressure, race and urinary electrolytes. Am J Epidemiol. 1976;104(2):124–32.
Katori M, Majima M. Renal (tissue) kallikrein-kinin system in the kidney and novel potential drugs for salt-sensitive hypertension. Prog Drug Res. 2014;69:59–109.
Share L. Role of vasopressin in cardiovascular regulation. Physiol Rev. 1988;68(4):1248–84.
Bankir L, Bouby N, Ritz E. Vasopressin: a novel target for the prevention and retardation of kidney disease? Nat Rev Nephrol. 2013;9(4):223–39.
Okada H, et al. Chronic and selective vasopressin blockade in spontaneously hypertensive rats. Am J Physiol. 1994;267(6 Pt 2):R1467–71.
Burrell LM, et al. Blood pressure-lowering effect of an orally active vasopressin V1 receptor antagonist in mineralocorticoid hypertension in the rat. Hypertension. 1994;23(6 Pt 1):737–43.
Burrell LM, et al. Age-dependent regulation of renal vasopressin V(1A) and V(2) receptors in rats with genetic hypertension: implications for the treatment of hypertension. J Am Soc Hypertens. 2013;7(1):3–13.
Naitoh M, et al. Modulation of genetic hypertension by short-term AVP V1A or V2 receptor antagonism in young SHR. Am J Physiol. 1997;272(2 Pt 2):F229–34.
Weber R, et al. Effects of SR 49059, a new orally active and specific vasopressin V1 receptor antagonist, on vasopressin-induced vasoconstriction in humans. Hypertension. 1997;30(5):1121–7.
Thibonnier M, et al. Effects of the nonpeptide V(1) vasopressin receptor antagonist SR49059 in hypertensive patients. Hypertension. 1999;34(6):1293–300.
Gavras H, et al. Effects of a specific inhibitor of the vascular action of vasopressin in humans. Hypertension. 1984;6(2 Pt 2):I156–60.
Gavras H. Role of vasopressin in clinical hypertension and congestive cardiac failure: interaction with the sympathetic nervous system. Clin Chem. 1991;37(10 Pt 2):1828–30.
Harris RC. Abnormalities in renal dopamine signaling and hypertension: the role of GRK4. Curr Opin Nephrol Hypertens. 2012;21(1):61–5.
Felder RA, Jose PA. Mechanisms of disease: the role of GRK4 in the etiology of essential hypertension and salt sensitivity. Nat Clin Pract Nephrol. 2006;2(11):637–50.
Svendsen UG. The importance of thymus in the pathogenesis of the chronic phase of hypertension in mice following partial infarction of the kidney. Acta Pathol Microbiol Scand A. 1977;85(4):539–47.
Bataillard A, et al. Antihypertensive effect of neonatal thymectomy in the genetically hypertensive LH rat. Thymus. 1986;8(6):321–30.
Idris-Khodja N, et al. Dual opposing roles of adaptive immunity in hypertension. Eur Heart J. 2014;35(19):1238–44.
Harrison DG, et al. Inflammation, immunity, and hypertension. Hypertension. 2011;57(2):132–40.
Cheng S, et al. Blood pressure tracking over the adult life course: patterns and correlates in the Framingham heart study. Hypertension. 2012;60(6):1393–9.
Burt VL, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension. 1995;25(3):305–13.
Bubb KJ, Khambata RS, Ahluwalia A. Sexual dimorphism in rodent models of hypertension and atherosclerosis. Br J Pharmacol. 2012;167(2):298–312.
Reckelhoff JF. Gender differences in the regulation of blood pressure. Hypertension. 2001;37(5):1199–208.
Charchar FJ, et al. Y is there a risk to being male? Trends Endocrinol Metab. 2003;14(4):163–8.
Reckelhoff JF, Zhang H, Granger JP. Testosterone exacerbates hypertension and reduces pressure-natriuresis in male spontaneously hypertensive rats. Hypertension. 1998;31(1 Pt 2):435–9.
Baltatu O, et al. Abolition of end-organ damage by antiandrogen treatment in female hypertensive transgenic rats. Hypertension. 2003;41(3 Pt 2):830–3.
Quan A, et al. Androgens augment proximal tubule transport. Am J Physiol Renal Physiol. 2004;287(3):F452–9.
Quinkler M, et al. Androgen receptor-mediated regulation of the alpha-subunit of the epithelial sodium channel in human kidney. Hypertension. 2005;46(4):787–98.
Dahl LK, et al. Role of the gonads in hypertension-prone rats. J Exp Med. 1975;142(3):748–59.
Masubuchi Y, et al. Gonadectomy-induced reduction of blood pressure in adult spontaneously hypertensive rats. Acta Endocrinol (Copenh). 1982;101(1):154–60.
Chappell MC, Yamaleyeva LM, Westwood BM. Estrogen and salt sensitivity in the female mRen(2). Lewis rat. Am J Physiol Regul Integr Comp Physiol. 2006;291(5):R1557–63.
Kang AK, Miller JA. Impact of gender on renal disease: the role of the renin angiotensin system. Clin Invest Med. 2003;26(1):38–44.
James GD, et al. Renin relationship to sex, race and age in a normotensive population. J Hypertens Suppl. 1986;4(5):S387–9.
Hollenberg NK, et al. Renal blood flow and its response to angiotensin II. An interaction between oral contraceptive agents, sodium intake, and the renin-angiotensin system in healthy young women. Circ Res. 1976;38(1):35–40.
Ellison KE, et al. Androgen regulation of rat renal angiotensinogen messenger RNA expression. J Clin Invest. 1989;83(6):1941–5.
Katz FH, Roper EF. Testosterone effect on renin system in rats. Proc Soc Exp Biol Med. 1977;155(3):330–3.
Chen YF, Naftilan AJ, Oparil S. Androgen-dependent angiotensinogen and renin messenger RNA expression in hypertensive rats. Hypertension. 1992;19(5):456–63.
Leung PS, et al. Androgen dependent expression of AT1 receptor and its regulation of anion secretion in rat epididymis. Cell Biol Int. 2002;26(1):117–22.
Miller JA, Anacta LA, Cattran DC. Impact of gender on the renal response to angiotensin II. Kidney Int. 1999;55(1):278–85.
Pechere-Bertschi A, Burnier M. Female sex hormones, salt, and blood pressure regulation. Am J Hypertens. 2004;17(10):994–1001.
Chobanian AV. Clinical practice. Isolated systolic hypertension in the elderly. N Engl J Med. 2007;357(8):789–96.
Lehoux S, et al. Pressure-induced matrix metalloproteinase-9 contributes to early hypertensive remodeling. Circulation. 2004;109(8):1041–7.
Dhingra R, et al. Relations of matrix remodeling biomarkers to blood pressure progression and incidence of hypertension in the community. Circulation. 2009;119(8):1101–7.
Nagareddy PR, et al. Inhibition of matrix metalloproteinase-2 improves endothelial function and prevents hypertension in insulin-resistant rats. Br J Pharmacol. 2012;165(3):705–15.
Jensky NE, et al. Blood pressure and vascular calcification. Hypertension. 2010;55(4):990–7.
Mente A, et al. Association of urinary sodium and potassium excretion with blood pressure. N Engl J Med. 2014;371(7):601–11.
Elliott P, et al. The INTERSALT study: main results, conclusions and some implications. Clin Exp Hypertens A. 1989;11(5–6):1025–34.
Chiolero A, Wurzner G, Burnier M. Renal determinants of the salt sensitivity of blood pressure. Nephrol Dial Transplant. 2001;16(3):452–8.